Brain metastasis in advanced colorectal cancer： results from the South Australian metastatic colorectal cancer (SAmCRC) registry

作     者：Gonzalo Tapia Rico Timothy J. Price Christos Karapetis Cynthia Piantadosi Rob Padbury Amitesh Roy Guy Maddern James Moore Scott Carruthers David Roder Amanda R. Townsend 

作者机构：Department of Medical Oncology The Queen Elizabeth Hospital and University of Adelaide Adelaide SA 5011 Australia Department of Medical Oncology Flinders Medical Center and Flinders University Adelaide SA 5042 Australia Department of Surgery Flinders Medical Center Bedford Park SA 5042 Australia Department of Surgery The Queen Elizabeth Hospital Adelaide SA 5011 Australia Department of Surgery University of South Australia Adelaide SA 5005 Australia Department of Surgery Royal Adelaide Hospital Adelaide SA 5000 Australia Department of Radiation Oncology Royal Adelaide Hospital Adelaide SA 5000 Australia Department of Epidemiology University of South Australia Adelaide SA 5005 Australia 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2017年第14卷第4期

页      面：371-376页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Brain metastasis colorectal cancer survival surveillance 

摘      要：Objective:Brain metastasis is considered rare in metastatic colorectal cancer(mCRC);thus,surveillance imaging does not routinely include the *** reported incidence of brain metastases ranges from 0.6% to 3.2%.Methods:The South Australian mCRC Registry(SAmCRC)was analyzed to assess the number of patients presenting with brain metastasis during their *** to small numbers,a descriptive analysis is ***:Only 59 patients of 4,100 on the registry at the time of analysis had developed brain metastasis(1.4%).The clinical characteristics of those with brain metastasis were as follows:the median age was 65.3 years and 51% were *** the V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog(KRAS)mutation status of the tumor was known,the majority harbored a KRAS mutation(55%);31(53%)underwent craniotomy and 55(93%)underwent whole-brain *** median survival time from diagnosis of brain metastasis was 4.2 months(95% confidence interval 2.9–5.5).Patients who underwent craniotomy and radiotherapy had superior survival compared to those who underwent whole-brain radiotherapy(8.5 months vs.2.2 months,respectively).Data from the SAmCRC(a population-based registry)confirm that brain metastases are rare and the median time to development is approximately 2 ***:Brain metastasis is a rare outcome in advanced *** within the registry tended to be female,young in age,and harbored with higher rates of KRAS *** routine surveillance brain scanning should be considered remains controversial given the relative rarity of developing brain metastases in mCRC and ultimately,most patients with central nervous system involvement die from their extracranial disease.